Avenda Health AI Prostate Cancer Planning Software vs Onclara™ (by Onc.ai)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Avenda Health AI Prostate Cancer Planning Software

by Avenda Health

Onclara™ (by Onc.ai)

by Onc.ai

AI Verdict

Avenda Health's Unfold AI is specifically designed for prostate cancer, creating 3D maps to aid in treatment planning and decision-making for personalized care. Onclara™ by Onc.ai, while also an oncology AI decision support tool, focuses on broader oncology applications, including improving clinical trial decision-making and predicting outcomes for metastatic lung cancer with immunotherapy. Therefore, they are adjacent competitors, with Avenda Health offering a specialized solution for a particular cancer type, while Onc.ai provides a more generalized platform for various oncology challenges.

Choose Avenda Health AI Prostate Cancer Planning Software if…

Choose Avenda Health AI Prostate Cancer Planning Software if you need precise, patient-specific 3D mapping of prostate cancer for treatment planning. This tool excels at visualizing tumor extent from various patient data sources (MRI, biopsy, pathology, PSA) to aid in decisions for active surveillance, prostatectomy, radiation, or focal therapy. It is particularly useful for improving the identification of tumor extent and predicting extracapsular extension risk, allowing for more confident surgical and treatment planning.

View Avenda Health AI Prostate Cancer Planning Software →

Choose Onclara™ (by Onc.ai) if…

Choose Onclara™ (by Onc.ai) if you are involved in oncology clinical trials or need predictive and prognostic models for metastatic lung cancer treated with immunotherapy. This platform leverages real-world oncology data to improve decision-making in Phase IB/Phase II clinical trials, including patient stratification and comparing treatment arms. It is also specifically designed to predict response and outcomes for metastatic lung cancer patients receiving immunotherapy, utilizing imaging AI and validated on comprehensive real-world datasets.

View Onclara™ (by Onc.ai) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Avenda Health AI Prostate Cancer Planning Software	Onclara™ (by Onc.ai)
Pricing	Contact for pricing	Unknown
Deployment	Cloud-based platform	Cloud-hosted (Onclara™ Studio, Microsoft Azure Foundry)
FDA Status	Yes AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Avenda Health AI Prostate Cancer Planning Software

Avenda Health AI's Unfold AI generates 3D cancer maps and integrates with interventional systems, suggesting a direct and intuitive workflow for physicians in treatment planning. While Onclarau2122 provides comprehensive PDF reports, the direct visualization and integration offered by Avenda Health AI likely provide a more immediate and interactive user experience for clinical decision-making.

Clinical Value

Avenda Health AI Prostate Cancer Planning Software

Avenda Health AI's Unfold AI is FDA-cleared and specifically designed to precisely map prostate cancer in 3D, improving tumor extent identification by 71% with over 98% sensitivity in studies. This directly impacts treatment planning and decision-making for personalized care. Onclarau2122 focuses on predictive and prognostic models for clinical trials and metastatic lung cancer, which is valuable but less broadly applicable to direct, real-time treatment planning across various cancer types compared to Avenda Health AI's specific and validated prostate cancer mapping.

Pricing & Value

Tie

Both tools require contacting the company for pricing, making a direct comparison of cost-effectiveness difficult. Avenda Health AI has a new Category III CPT code for reimbursement, which could improve its value proposition for providers, but the extent of insurance coverage is still developing. Without specific pricing details for either, it's impossible to definitively declare a winner in this dimension.

Enterprise Readiness

Onclara™ (by Onc.ai)

Onclarau2122 is deployed on Microsoft Azure Foundry and offers an API, indicating a robust and scalable infrastructure suitable for enterprise integration. While Avenda Health AI is cloud-based and HIPAA compliant, the explicit mention of an API and a well-known enterprise cloud platform for Onclarau2122 suggests a higher degree of enterprise readiness for broader integration and data exchange.

Innovation

Avenda Health AI Prostate Cancer Planning Software

Avenda Health AI's Unfold AI uses AI to create precise 3D cancer estimation maps from multiple data sources, offering a novel approach to visualizing and planning prostate cancer treatment. This direct spatial mapping and integration with interventional systems represents a significant innovation in personalized oncology. Onclarau2122 focuses on predictive and prognostic models using real-world data, which is valuable, but the 3D mapping and direct surgical planning aid of Avenda Health AI appears to be a more distinct and impactful innovation in clinical practice.

Support & Docs

Tie

Neither the provided structured facts nor general web searches offer specific details regarding the level of customer support, training, or documentation available for either Avenda Health AI or Onclarau2122. Without this information, it is not possible to distinguish between the two tools in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Avenda Health AI Prostate Cancer Planning Software	Onclara™ (by Onc.ai)
Name	Avenda Health AI Prostate Cancer Planning Software	Onclarau2122 (by Onc.ai)
Company	Avenda Health	Onc.ai
Tagline	Bringing Confidence to your Prostate Cancer Treatment Decisions	AI-powered technology bringing clarity to cancer treatment decisions.
Categories	Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI	Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI
Specialties	Oncology, Radiology, Urology	Oncology, Pulmonology, Radiology
Key Features	AI-based decision support for prostate cancer planning, Generates 3D Cancer Estimation Maps (CEM) from MRI, biopsy, pathology, and PSA data, Precisely maps prostate cancer location and extent in 3D, Aids in surgical planning and treatment decision-making (active surveillance, prostatectomy, radiation, focal therapy), Improves identification of tumor extent (71% improvement, over 98% sensitivity in studies), Supports segmentation of MR image features and lesion documentation, Data exportable to compatible interventional or biopsy systems, Predicts extracapsular extension (ECE) risk	AI-powered predictive and prognostic models, Leverages real-world oncology datasets, Improves Phase IB/Phase II clinical trial decision-making, Predicts response and outcomes for metastatic lung cancer with immunotherapy, Imaging AI for oncology, Serial Imaging Response Score (SIRS), Validated on comprehensive real-world datasets (e.g., Flatiron Health)
Data Export	Data exportable to compatible interventional or biopsy systems	Oncologists receive a comprehensive PDF report.

Videos

Demos, reviews, and walkthroughs featuring Avenda Health AI Prostate Cancer Planning Software and Onclara™ (by Onc.ai).

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing oncology or urology workflows, and what is the typical learning curve for physicians and their teams?

Avenda Health's Unfold AI generates 3D cancer estimation maps from various patient data points, aiding in surgical planning and treatment decisions for prostate cancer. Onclarau2122 focuses on predictive and prognostic models for oncology, particularly for metastatic lung cancer with immunotherapy, and provides comprehensive PDF reports. The learning curve for Avenda Health would involve understanding the 3D mapping and its application in treatment planning, while Onclarau2122 would require familiarization with its predictive models and interpreting the generated reports.

What is the depth of EHR integration for each tool, and how does data flow between the tools and our current systems?

Avenda Health's Unfold AI creates 3D cancer maps from patient MRI, biopsy, pathology, and PSA data, and the data is exportable to compatible interventional or biopsy systems. Onclarau2122 leverages real-world oncology datasets and provides oncologists with a comprehensive PDF report, suggesting a data export mechanism for integration. The specifics of direct EHR integration and data flow would need to be further investigated for both platforms.

Beyond prostate cancer for Avenda Health and metastatic lung cancer for Onclarau2122, what other oncology specialties or cancer types are these tools designed to support, and what is their accuracy/sensitivity in those areas?

Avenda Health's Unfold AI is specifically designed for prostate cancer planning, improving identification of tumor extent by 71% and demonstrating over 98% sensitivity in studies, and also predicts extracapsular extension (ECE) risk. Onclarau2122 focuses on improving oncology decision-making in clinical trials and practice, with a specific feature for predicting response and outcomes for metastatic lung cancer with immunotherapy. While Onclarau2122 is broadly categorized for oncology, pulmonology, and radiology, its validated accuracy and sensitivity are highlighted for metastatic lung cancer.

What kind of support is available for physicians during implementation and ongoing use, and what is the typical time-to-value for each solution?

Both companies aim to provide clarity and confidence in treatment decisions, suggesting a focus on user support. Avenda Health's Unfold AI aids in treatment planning and decision-making for personalized care, implying a rapid time-to-value by streamlining this process. Onclarau2122 aims to improve oncology decision-making in clinical trials and practice, which could translate to value through more informed treatment strategies and potentially better patient outcomes. Specific details on support quality and time-to-value would likely be discussed during the sales process.

What audit-trail features are available in each tool to track how AI-generated insights are used in clinical decision-making, and how does each tool ensure data security beyond standard compliance?

Avenda Health's Unfold AI generates 3D cancer estimation maps from patient data to aid in treatment planning, suggesting that the output itself serves as a record of the AI's contribution to the decision. Onclarau2122 provides comprehensive PDF reports to oncologists, which could serve as an audit trail for the AI's predictive and prognostic models. Both platforms are cloud-based, implying robust underlying security infrastructure, but specific audit-trail features and security measures beyond HIPAA compliance would need to be detailed by each vendor.

Can these tools be easily rolled out across multiple clinical sites, and what considerations should be made for a multi-site implementation?

Both Avenda Health's Unfold AI and Onclarau2122 are cloud-based platforms, which generally facilitates multi-site rollouts due to centralized access and management. For Avenda Health, considerations would include integrating with various imaging and biopsy systems across sites. For Onclarau2122, ensuring consistent data input and interpretation of predictive models across different clinical environments would be important. The scalability of their cloud infrastructure would be a key factor for multi-site implementation.

Are there customer references or case studies available that demonstrate the real-world impact and physician experience with these tools?

Avenda Health highlights that its Unfold AI improves identification of tumor extent by 71% with over 98% sensitivity in studies, suggesting clinical validation. Onclarau2122 mentions that its models are validated on comprehensive real-world datasets (e.g., Flatiron Health). While these indicate a basis in real-world data and studies, direct customer references or detailed case studies on physician experience would be valuable to assess the practical impact of each tool.

More Comparisons

eCARTv5 Clinical Deterioration Suite (eCART) vs Google Med-PaLM 2

ChatGPT vs Google Med-PaLM 2

When choosing between ChatGPT and Google Med-PaLM 2, physicians should consider their primary use case and desired level of medical…

Brainomix 360 e-CTA vs Google Med-PaLM 2

DeepXray vs Google Med-PaLM 2

More matchups featuring Avenda Health AI Prostate Cancer Planning Software or Onclara™ (by Onc.ai)

Backers

Who funded each tool's parent company.

Avenda Health AI Prostate Cancer Planning Software

E12 Ventures

Onclara™ (by Onc.ai)

LifeX Ventures